The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participants in terms of disease symptomatology/control, fatigue, work impairment, patient's relationship with their skin, and overall QOL among adult participants.
Adult (greater than or equal to [>=] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.
Adult participants prescribed lebrikizumab as part of routine/usual care to manage their moderate-to severe Atopic dermatitis.
Willingness and ability to participate in the study; participants must give their written consent to participate.
Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®).
Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.
Concomitant use of live and live attenuated vaccines.
Pregnant women, except when the potential benefit justifies the potential risk.